{"id":"NCT03349333","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","briefTitle":"A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL","officialTitle":"A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-10","primaryCompletion":"2017-07-21","completion":"2018-05-21","firstPosted":"2017-11-21","resultsPosted":"2019-09-12","lastUpdate":"2019-10-01"},"enrollment":85,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Peripheral T-Cell Lymphoma","Relapsed T-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"pralatrexate","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin B12 and folic acid","otherNames":[]}],"arms":[{"label":"pralatrexate","type":"EXPERIMENTAL"}],"summary":"This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).","primaryOutcome":{"measure":"Objective Response Rate(ORR) by International Working Group Criteria","timeFrame":"2 years","effectByArm":[{"arm":"Pralatrexate","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["30904980"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":71},"commonTop":["Stomatitis","Neutropenia"]}}